Director of Operations Cell Therapy and Transplant at the Hospital of the University of Pennsylvania

Summary:

• The Director of Operations will oversee operations of the Cell Therapy and Transplant program at all locations and will oversee operations that support all facets of the CTT program, including CIBMTR reporting, Autologous transplant, Allogeneic transplant, and Cell Therapy programs, and the Quality programs that support CTT at all locations. The Director of Operations will be responsible for creating a regional system of CTT and will be responsible for aligning standardized procedures where possible, common KPIs, and integrated quality and safety protocols. The Director of Operations will lead the operational management of the current BMT and non-BMT cell therapy programs as well as oversee operational development of new programs and will work with local CTT sites to utilize resources as needed. This leadership will require the Director to collaborate with clinical and administrative leadership across Penn Medicine and to interface/interact with outside entities, such as NMDP, CIBMTR, FACT, Pharma, ASTCT, etc. to ensure that the program is developing to industry standards/accreditations. The Director of Operations reports directly to the Corporate Director of CTT and partners in the execution of strategic growth and regional expansion with the Director of the CTT program and the Cancer Service Line (CSL). This includes chairing the CSL CTT Operations Committee; partnering with executive, clinical, and administrative leadership at all Penn Medicine hospitals to further the expansion and implementation of the CTT program; and managing external stakeholder activities in pursuit of Penn Medicine system solutions given current and future infrastructure. Ensures safety, accreditation, and compliance programs are aligned across Penn Medicine to achieve the highest levels of performance. Non-Oncology: Through this expanded scope, the Director will partner with the clinical and research physician leaders across a variety of Departments and Divisions that are exploring new and innovative cellular therapy programs. Such Departments and Divisions include Medicine, Neurology, Benign Hematology. This list of clinical and research collaborators continues to expand as the non-oncology cellular therapy industry rapidly grows. In addition, the Director will be responsible for interacting with relevant pharmaceutical companies and third-party institutions to establish procedures, protocols, contracts, regulatory standards and processes, and all other necessary services to initiate both clinical trials and clinical care across UPHS.